REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.
The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.
Details of the abstracts are listed below:
Revolution Medicines Oral Presentations:
| Title: | Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors |
| Presenter: | Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | CT019 |
| Session: | New Frontiers in Precision Oncology |
| Date/Time: | April 27; 5:00 p.m. – 5:15 p.m. CST |
| Title: | Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor |
| Presenter: | Anne Edwards, Ph.D. |
| Abstract Number: | ND06 |
| Session: | New Drugs on the Horizon: Part 2 |
| Date/Time: | April 27; 3:25 p.m. – 3:40 p.m. CST |
Revolution Medicines Poster Presentations:
| Title: | Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) |
| Presenter: | Jia Luo, M.D., Dana-Farber Cancer Institute |
| Abstract Number: | LB218 |
| Session: | Late-Breaking Research: Clinical Research 1 |
| Date/Time: | April 28; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies |
| Presenter: | Mallika Singh, Ph.D. |
| Abstract Number: | LB281 |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Date/Time: | April 29; 9:00 a.m. – 12:00 p.m. CST |
| Title: | Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy |
| Presenter: | Mariela Moreno Ayala, Ph.D. |
| Abstract Number: | 6046 |
| Session: | Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
Collaborator Presentations
| Title: | Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models |
| Presenter: | Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | LB293 |
| Session: | Late-Breaking Research: Experimental and Molecular Therapeutics 3 |
| Date/Time: | April 29; 9:00 a.m. – 12:00 p.m. CST |
| Title: | Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation |
| Presenter: | Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center |
| Abstract Number: | 5512 |
| Session: | Drug Resistance in Molecular Targeted Therapies 3 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC |
| Presenter: | Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | 5336 |
| Session: | CDK Inhibitors |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma |
| Presenter: | Jingjing Jiang, Ph.D. |
| Abstract Number: | 5691 |
| Session: | Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer |
| Presenter: | Joshua H. Choe, Dana-Farber Cancer Institute |
| Abstract Number: | 5507 |
| Session: | Drug Resistance in Molecular Targeted Therapies 3 |
| Date/Time: | April 29; 2:00 p.m. – 5:00 p.m. CST |
| Title: | T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC |
| Presenter: | Margo I. Orlen, Penn Medicine |
| Abstract Number: | 6405 |
| Session: | Checkpoints and Modulators of Tumor Microenvironment |
| Date/Time: | April 29; 3:25 p.m. – 3:40 p.m. CST |
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$34.60 |
| Daily Change: | 0.98 2.91 |
| Daily Volume: | 3,708,227 |
| Market Cap: | US$6.390B |
February 26, 2025 December 02, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
